NOTCH1 and B-cell chronic lymphocytic leukemia: Although a trend for adverse PFS and lower undetectable minimal residual disease is found in NOTCH1-mutated CLL cases [24,54], further validation is necessarily required in other cohorts before drawing conclusions about the effect of NOTCH1 mutation in venetoclax-based regimens (Table 1).